TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth
Chan, Tsz-Yin, Egbert, Christina M., Maxson, Julia E., Siddiqui, Adam, Larsen, Logan J., Kohler, Kristina, Balasooriya, Eranga Roshan, Pennington, Katie L., Tsang, Tsz-Ming, Frey, Madison, Soderblom, Erik J., Geng, Huimin, Müschen, Markus, Forostyan, Tetyana V., Free, Savannah, Mercenne, Gaelle, Banks, Courtney J., Valdoz, Jonard, Whatcott, Clifford J., Foulks, Jason M., Bearss, David J., O’Hare, Thomas, Huang, David C. S., Christensen, Kenneth A., Moody, James, Warner, Steven L., Tyner, Jeffrey W., Andersen, Joshua L.
Published in Nature communications (09.09.2021)
Published in Nature communications (09.09.2021)
Get full text
Journal Article
Abstract 1478: TP-5809, a novel TNK1 inhibitor, suppresses TNK1 dependent signaling and tumor growth in a preclinical model of Hodgkin's lymphoma
Forostyan, Tetyana V., Tyagi, Ethika, Foulks, Jason M., Lalonde, Matthew, Andersen, Joshua L., Siddiqui, Adam, Whatcott, Clifford J., Bearss, David, Warner, Steve
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models
Forostyan, Tetyana V, Weagel, Evita, Matsumura, Yuta, Tyagi, Ethika, Foulks, Jason M, Whatcott, Clifford J, Siddiqui-Jain, Adam, Bearss, David J, Warner, Steven L
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Abstract 1617: TGFBR1 as a novel therapeutic target in adult granulosa cell tumors
Allred, Curtis A., Heinz, Richard E., Matsumura, Yuta, Forostyan, Tetyana V., Kircher, David, Sommakia, Salah, Welte, Thomas, Vuttaradhi, Veena, Foulks, Jason M., Warner, Steven L., Hillman, R Tyler
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 2853: TP-6379, an investigational TGFBR1 inhibitor, shows improvement in survival and enhances activity of standard of care in preclinical ovarian cancer models
Forostyan, Tetyana V., Kircher, David A., Heinz, Richard E., Allred, Curtis, Sommakia, Sal, Matsumura, Yuta, Siddiqui, Adam, Foulks, Jason M., Warner, Steven L.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 5171: TP-6379, an investigational TGFBR1 inhibitor, shown to remodel the tumor microenvironment and enhance anti-tumorigenic immunological responses in syngeneic mouse models of cancer
Kircher, David A., Forostyan, Tetyana V., Heinz, Richard E., Allred, Curtis A., Sommakia, Sal, Matsumura, Yuta, Siddiqui, Adam, Foulks, Jason M., Warner, Steven L.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article